Olaford 5 Plus Tablet is a combination pharmaceutical formulation containing Fluoxetine 20 mg and Olanzapine 5 mg, indicated for the management of various psychiatric disorders including major depressive disorder with psychotic features, bipolar disorder, and treatment-resistant depression. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), functions by increasing serotonin levels in the brain, thereby improving mood and alleviating symptoms of depression and anxiety. Olanzapine, an atypical antipsychotic, acts by modulating dopamine and serotonin receptors, contributing to the reduction of psychotic symptoms, mood stabilization, and enhancement of overall therapeutic efficacy when combined with Fluoxetine. This combination is particularly useful in patients who exhibit both depressive and psychotic symptoms or those who have not responded adequately to monotherapy. Olaford 5 Plus should be administered under strict medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include weight gain, sedation, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizure disorders. Regular monitoring of metabolic parameters and mental status is recommended to ensure safety and optimize treatment outcomes. This medication is contraindicated in individuals with known hypersensitivity to either component.